Search

Displaying results 2601 - 2610 of 10000 in total
  1. Drug

    Trilostane

    go.drugbank.com/drugs/DB01108
    ApprovedVet approvedWithdrawn

    Trilostane is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994.

  2. Drug

    Isoflavone

    go.drugbank.com/drugs/DB12007
    ApprovedInvestigationalWithdrawn

    Isoflavone is found as one of constituents in oral over-the-counter dietary supplements indicated for improved bone mass density and body fat regulation. … The main soy isoflavones are mostly present in glycosylated forms and include [DB01645], [DB13182], and glycitein, which accounts for approximately 50%, 40%, and 10%, respectively, of the total soybean

  3. Drug

    Chlorquinaldol

    go.drugbank.com/drugs/DB13306
    Approved

    [F4549] It was marketed in the 1950s as an iodine-free alternative which was also unrelated to sulfa drugs or hormones.

  4. Drug

    Doxecitine

    go.drugbank.com/drugs/DB02594
    ApprovedInvestigational

    It is an essential component of the deoxyribonucleotide pool required for DNA synthesis and repair.

  5. Drug

    Prenylamine

    go.drugbank.com/drugs/DB04825
    ApprovedWithdrawn

    Prenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.

    Categories: Vasodilators Used in Cardiac DiseasesSynonyms: N-(3,3-Diphenylpropyl)-alpha-methylphenaethylamin, N-(3,3-Diphenylpropyl)-alpha-methylphenethylamine
  6. Drug

    Thyroid, porcine

    go.drugbank.com/drugs/DB09100
    ApprovedInvestigational

    [A190813] Thyroid extracts were never FDA approved as their use in the United States predates the FDA.[A190831] … [A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891[A190807] but its use dates back as far as the 6th century.

  7. Drug

    Vemurafenib

    go.drugbank.com/drugs/DB08881
    ApprovedInvestigational

    After approval, Roche in collaboration with Genentech launched a broad development program. [L1012] … [A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche.

  8. Drug

    Givinostat

    go.drugbank.com/drugs/DB12645
    ApprovedInvestigational

    [L50316,A263446] Givinostat was granted FDA approval in March 2024 for the treatment of patients ≥6 years of age with Duchenne muscular dystrophy (DMD). … In the context of muscular dystrophy, inhibitors of HDAC appear to exert their therapeutic effects by targeting pathogenic processes that cause inflammation and muscle loss.

  9. Drug

    Isavuconazonium

    go.drugbank.com/drugs/DB06636
    ApprovedInvestigational

    Due to low solubility in water of isavuconazole on its own, the isovuconazonium formulation is favorable as it has high solubility in water and allows for intravenous administration. … [A6913,A6914,A262706] On December 08, 2023, the FDA approved the expanded use of isovuconazonium in pediatric patients for the same indications.[L49251]

  10. Drug

    Ocrelizumab

    go.drugbank.com/drugs/DB11988
    ApprovedInvestigational

    In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a]. … It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada.